DE602006009077D1 - Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung - Google Patents

Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung

Info

Publication number
DE602006009077D1
DE602006009077D1 DE602006009077T DE602006009077T DE602006009077D1 DE 602006009077 D1 DE602006009077 D1 DE 602006009077D1 DE 602006009077 T DE602006009077 T DE 602006009077T DE 602006009077 T DE602006009077 T DE 602006009077T DE 602006009077 D1 DE602006009077 D1 DE 602006009077D1
Authority
DE
Germany
Prior art keywords
ala
leu
seq
thr
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006009077T
Other languages
English (en)
Inventor
Yu-Chun Lone
Anthony Pajot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006009077(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602006009077D1 publication Critical patent/DE602006009077D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE602006009077T 2005-02-25 2006-02-24 Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung Active DE602006009077D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0550520A FR2882557A1 (fr) 2005-02-25 2005-02-25 Epitopes de vih et composition pharmaceutique les contenant
PCT/FR2006/050167 WO2006090090A2 (fr) 2005-02-25 2006-02-24 Epitopes de vih et composition pharmaceutique les contenant

Publications (1)

Publication Number Publication Date
DE602006009077D1 true DE602006009077D1 (de) 2009-10-22

Family

ID=34954973

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006009077T Active DE602006009077D1 (de) 2005-02-25 2006-02-24 Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung

Country Status (9)

Country Link
US (1) US20110142911A1 (de)
EP (1) EP1851321B1 (de)
JP (1) JP2008531530A (de)
AT (1) ATE442451T1 (de)
CA (1) CA2598929A1 (de)
DE (1) DE602006009077D1 (de)
ES (1) ES2332532T3 (de)
FR (1) FR2882557A1 (de)
WO (1) WO2006090090A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2535034C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
KR101476255B1 (ko) * 2014-02-07 2014-12-26 대한민국 HIV-l 유래 T 세포 항원결정기를 갖는 재조합 펩타이드 및 이를 포함하는 백신 조성물
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
TW202110870A (zh) 2019-05-30 2021-03-16 美商葛利史東腫瘤科技公司 經修飾之腺病毒
WO2020248032A1 (pt) * 2019-06-10 2020-12-17 Ricardo Diaz Método para a definição de uma vacina personalizada contra o hiv/aids
WO2021003348A1 (en) * 2019-07-02 2021-01-07 Gritstone Oncology, Inc. Hiv antigens and mhc complexes
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650175T3 (de) * 1985-04-29 2007-09-06 Bio-Rad Laboratories, Inc., Hercules Synthetische antigene zum nachweis von aids.
US5034511A (en) * 1987-04-13 1991-07-23 Institut Pasteur Variant of LAV viruses
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
ATE228248T1 (de) * 1997-03-10 2002-12-15 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv- antigenen und hiv-antikörpern
WO2001072298A1 (en) * 2000-03-27 2001-10-04 The General Hospital Corporation Treatments for immune-mediated ear disorders
AU2003245729A1 (en) * 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US7663017B2 (en) * 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications

Also Published As

Publication number Publication date
FR2882557A1 (fr) 2006-09-01
ES2332532T3 (es) 2010-02-08
JP2008531530A (ja) 2008-08-14
WO2006090090A2 (fr) 2006-08-31
EP1851321B1 (de) 2009-09-09
ATE442451T1 (de) 2009-09-15
CA2598929A1 (fr) 2006-08-31
US20110142911A1 (en) 2011-06-16
WO2006090090A3 (fr) 2006-12-07
EP1851321A2 (de) 2007-11-07

Similar Documents

Publication Publication Date Title
Tan et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques
Neidleman et al. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
Geluk et al. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A* 0201-restricted CD8+ T cells in HLA-transgenic mice and humans
DE602006009077D1 (de) Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung
Earnhart et al. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences
Pardieck et al. A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection
CN106103471A (zh) 异源寡聚分枝杆菌抗原的融合
JP2007526318A (ja) Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅに対する免疫原性組成物
Remakus et al. Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease
CN104918960A (zh) 改进的人类疱疹病毒免疫疗法
JPH03503166A (ja) 抗ｈｉｖ応答を喚起する合成抗原
WO2007005627A3 (en) Tuberculosis antigen detection assays and vaccines
Hauser et al. Engineered receptor binding domain immunogens elicit pan-coronavirus neutralizing antibodies outside the receptor binding motif
Zivny et al. A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities.
Romano et al. Induction of in vivo functional Db-restricted cytolytic T cell activity against a putative phosphate transport receptor of Mycobacterium tuberculosis
Joshi et al. Flexibility in MHC and TCR recognition: degenerate specificity at the T cell level in the recognition of promiscuous Th epitopes exhibiting no primary sequence homology
CA2416761A1 (fr) Procede de criblage de peptides utilisables en immunotherapie
Boesen et al. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2. 1 transgenic mice
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
WO2001016174A9 (en) Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65
CN101370517B (zh) 来源于c型肝炎病毒的肽
Gadzinski et al. Transfer of the ability of HIV-1 Tat to raise an adjuvant-free humoral immune response to unrelated antigens
WO2007049394A1 (ja) Ｃ型肝炎ウイルス由来ペプチド
Fonseca et al. Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis
ES2573105T3 (es) Secuencias de péptidos y composiciones

Legal Events

Date Code Title Description
8363 Opposition against the patent